tiprankstipranks
Trending News
More News >

TScan Therapeutics price target lowered to $10 from $15 at H.C. Wainwright

H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on TScan Therapeutics (TCRX) to $10 from $15 and keeps a Buy rating on the shares. The firm lowered its valuation multiples and increased the stock’s discount rates to better align with current investor sentiment, elevated cost of capital, and reduced appetite for early-stage clinical risk.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1